Gene Solutions and Pangea Laboratory Join Forces for Cancer Testing Innovations

Gene Solutions, a global biotechnology company, and Pangea Laboratory, a leader in Next Generation Sequencing (NGS) validation, have announced a strategic collaboration aimed at enhancing the verification and clinical validation of liquid biopsy assays designed for cancer detection. This partnership, revealed on January 21, 2026, will focus on advancing the use of these tests within the U.S. healthcare system.

Under the terms of the agreement, Gene Solutions will provide standard operating procedures (SOPs), funding, and technical support from its CAP-accredited laboratories located in Singapore and Vietnam. Pangea Laboratory will manage all analytical and clinical validation processes at its facilities in Irvine, California. This collaboration is expected to facilitate the introduction of Gene Solutions’ AI-powered multi-omics liquid biopsy technologies into the U.S. market while adhering to CLIA and CAP quality standards.

Combining Expertise for Enhanced Cancer Care

Dr. Hoa Giang, Co-founder and Chief Data Science Officer of Gene Solutions, expressed enthusiasm about the partnership, stating, “Through our collaboration with Pangea, we’re combining Gene Solutions’ AI-driven multi-omics innovation with world-class U.S. validation expertise. Together, we aim to deliver affordable, advanced cancer detection, tumor profiling, and monitoring tools.”

The initial phase of the collaboration will prioritize two flagship NGS tests developed by Gene Solutions. These tests are designed to improve cancer detection and monitoring, making significant strides in precision medicine.

John Moore, CEO of Pangea Laboratory, emphasized the importance of this collaboration, noting, “Pangea is pleased to support the advancement of SPOT-MAS and K-4CARE in the U.S. market, which are complementary to Pangea’s Bladder CARETM assay for the early detection of bladder cancer. Our validation platform is designed specifically for innovative Laboratory Developed Tests, and we look forward to helping clinicians and patients benefit from these technologies.”

About the Companies Involved

Founded in 2014, Pangea Laboratory is recognized for its expertise in high-complexity testing and validation services, holding CLIA certification and CAP accreditation. The company specializes in innovative assays, including NGS and molecular diagnostics. More details about their offerings can be found on their website.

Gene Solutions operates as a global biotechnology company headquartered in Singapore, focusing on making advanced genomic solutions widely available. The company leverages multi-omics, NGS, and AI technologies to provide a diverse portfolio, including multicancer early detection tests like SPOT-MAS and comprehensive tumor profiling with ctDNA monitoring such as K-TRACK and K-4CARE. Since its inception in 2017, Gene Solutions has performed millions of genetic tests worldwide.

As this collaboration unfolds, both companies aim to enhance the landscape of cancer care by providing clinicians and patients with cutting-edge diagnostic tools. The partnership reflects a commitment to improving healthcare outcomes through innovation and collaboration.

Important disclaimer: Some tests may be offered as Laboratory Developed Tests (LDTs) in CLIA-certified, CAP-accredited laboratories; availability and institutional policies vary by state and health system. Results are intended for professional use only. SPOT-MAS is recommended for adults at elevated cancer risk and should complement guideline-recommended screening; it does not detect all cancers.

This announcement includes forward-looking statements that are subject to risks and uncertainties. Neither Gene Solutions nor Pangea Laboratory has any obligation to update these statements.